FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200401708> ?p ?o ?g. }

• W4200401708 endingPage "108686" @default.
• W4200401708 startingPage "108686" @default.
• W4200401708 abstract "Background Medications for opioid use disorder (MOUDs), including methadone, buprenorphine and naltrexone, are associated with lower death rates and improved quality of life for people in recovery from opioid use disorder (OUD). Less is known about each MOUD modality's association with treatment retention and the contribution of behavioral health therapy (BHT). The objectives of the current study were to estimate the association between MOUD type and treatment retention and determine whether BHT was associated with length of time retained. Methods We investigated the time from initiation to discontinuation from MOUD by medication type and exposure to BHT using statewide Medicaid Claims data (N = 81,752). We estimated covariate adjusted hazard ratios (AHR) using a Cox proportional hazards model. Results Compared to methadone, buprenorphine was associated with a higher risk of discontinuation at the time of initiation (AHR = 2.41, 95% CI = 2.28–2.55), however that difference decreased over one year of maintained retention (AHR = 1.44, 95% CI = 1.37–1.50). Compared to methadone and buprenorphine, naltrexone was associated with a higher risk of discontinuation at the time of initiation (naltrexone vs. methadone AHR = 2.49, 95% CI = 2.30–2.65; naltrexone vs. buprenorphine AHR 1.03, 95% CI = 1.00–1.07), and that relative risk increased over the course of one year of retention (naltrexone vs. methadone AHR = 3.85, 95% CI = 3.63–4.09; naltrexone vs. buprenorphine AHR = 2.67, 95% CI = 2.54–2.81). In general, independent of MOUD type, exposure to BHT during MOUD treatment was associated with a lower risk of discontinuation (AHR = 0.94, 95% CI = 0.92–0.96). However, BHT during the treatment episode was not associated with retention in the adolescent/young adult and pregnant women subpopulations. Discussion From the standpoint of early success, methadone was associated with the lowest risk of treatment discontinuation. While buprenorphine and naltrexone were associated with similar risks at the beginning of treatment, the relative discontinuation risk for buprenorphine was less than half that of naltrexone at one year of retention. In general, BHT with MOUD was associated with a lower risk of treatment discontinuation." @default.
• W4200401708 created "2021-12-31" @default.
• W4200401708 creator A5006147059 @default.
• W4200401708 creator A5008936415 @default.
• W4200401708 creator A5020160090 @default.
• W4200401708 creator A5035822286 @default.
• W4200401708 creator A5038109806 @default.
• W4200401708 creator A5049319871 @default.
• W4200401708 creator A5064949219 @default.
• W4200401708 creator A5076330540 @default.
• W4200401708 creator A5090808465 @default.
• W4200401708 date "2022-05-01" @default.
• W4200401708 modified "2023-09-26" @default.
• W4200401708 title "Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data" @default.
• W4200401708 cites W1989488351 @default.
• W4200401708 cites W1998888892 @default.
• W4200401708 cites W2037459329 @default.
• W4200401708 cites W2045066965 @default.
• W4200401708 cites W2059678901 @default.
• W4200401708 cites W2076293542 @default.
• W4200401708 cites W2153599479 @default.
• W4200401708 cites W2404633355 @default.
• W4200401708 cites W2566316894 @default.
• W4200401708 cites W2605608745 @default.
• W4200401708 cites W2729232923 @default.
• W4200401708 cites W2734430838 @default.
• W4200401708 cites W2745708468 @default.
• W4200401708 cites W2781874148 @default.
• W4200401708 cites W2801711697 @default.
• W4200401708 cites W2809380555 @default.
• W4200401708 cites W2886457436 @default.
• W4200401708 cites W2887857414 @default.
• W4200401708 cites W2890254074 @default.
• W4200401708 cites W2900428488 @default.
• W4200401708 cites W2906591149 @default.
• W4200401708 cites W2944661632 @default.
• W4200401708 cites W2990187794 @default.
• W4200401708 cites W3005454586 @default.
• W4200401708 cites W3179112797 @default.
• W4200401708 doi "https://doi.org/10.1016/j.jsat.2021.108686" @default.
• W4200401708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34953637" @default.
• W4200401708 hasPublicationYear "2022" @default.
• W4200401708 type Work @default.
• W4200401708 citedByCount "5" @default.
• W4200401708 countsByYear W42004017082022 @default.
• W4200401708 countsByYear W42004017082023 @default.
• W4200401708 crossrefType "journal-article" @default.
• W4200401708 hasAuthorship W4200401708A5006147059 @default.
• W4200401708 hasAuthorship W4200401708A5008936415 @default.
• W4200401708 hasAuthorship W4200401708A5020160090 @default.
• W4200401708 hasAuthorship W4200401708A5035822286 @default.
• W4200401708 hasAuthorship W4200401708A5038109806 @default.
• W4200401708 hasAuthorship W4200401708A5049319871 @default.
• W4200401708 hasAuthorship W4200401708A5064949219 @default.
• W4200401708 hasAuthorship W4200401708A5076330540 @default.
• W4200401708 hasAuthorship W4200401708A5090808465 @default.
• W4200401708 hasConcept C118552586 @default.
• W4200401708 hasConcept C126322002 @default.
• W4200401708 hasConcept C160735492 @default.
• W4200401708 hasConcept C162324750 @default.
• W4200401708 hasConcept C170493617 @default.
• W4200401708 hasConcept C207103383 @default.
• W4200401708 hasConcept C2776534028 @default.
• W4200401708 hasConcept C2777972943 @default.
• W4200401708 hasConcept C2778715236 @default.
• W4200401708 hasConcept C2778767360 @default.
• W4200401708 hasConcept C2778949969 @default.
• W4200401708 hasConcept C2779418921 @default.
• W4200401708 hasConcept C2781063702 @default.
• W4200401708 hasConcept C38652104 @default.
• W4200401708 hasConcept C40010229 @default.
• W4200401708 hasConcept C41008148 @default.
• W4200401708 hasConcept C42219234 @default.
• W4200401708 hasConcept C44249647 @default.
• W4200401708 hasConcept C50522688 @default.
• W4200401708 hasConcept C71924100 @default.
• W4200401708 hasConcept C79736992 @default.
• W4200401708 hasConceptScore W4200401708C118552586 @default.
• W4200401708 hasConceptScore W4200401708C126322002 @default.
• W4200401708 hasConceptScore W4200401708C160735492 @default.
• W4200401708 hasConceptScore W4200401708C162324750 @default.
• W4200401708 hasConceptScore W4200401708C170493617 @default.
• W4200401708 hasConceptScore W4200401708C207103383 @default.
• W4200401708 hasConceptScore W4200401708C2776534028 @default.
• W4200401708 hasConceptScore W4200401708C2777972943 @default.
• W4200401708 hasConceptScore W4200401708C2778715236 @default.
• W4200401708 hasConceptScore W4200401708C2778767360 @default.
• W4200401708 hasConceptScore W4200401708C2778949969 @default.
• W4200401708 hasConceptScore W4200401708C2779418921 @default.
• W4200401708 hasConceptScore W4200401708C2781063702 @default.
• W4200401708 hasConceptScore W4200401708C38652104 @default.
• W4200401708 hasConceptScore W4200401708C40010229 @default.
• W4200401708 hasConceptScore W4200401708C41008148 @default.
• W4200401708 hasConceptScore W4200401708C42219234 @default.
• W4200401708 hasConceptScore W4200401708C44249647 @default.
• W4200401708 hasConceptScore W4200401708C50522688 @default.
• W4200401708 hasConceptScore W4200401708C71924100 @default.
• W4200401708 hasConceptScore W4200401708C79736992 @default.

• next